IP Library Patent Application 11740035
Patent Application
App. No. 11/740,035

METHOD FOR TREATING CARTILAGE DEFECTS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/740,035
Abstract

Methods for treating a cartilage defect comprising fractioning blood to produce a blood component, shaping the cartilage defect to expose subchondral bone, microfracturing the subchondral bone, and applying the blood component to the microfractured subchondral bone. The blood component can comprise platelet-poor plasma.

Claims (15)

1 . A method for treating a cartilage defect in a human subject comprising:

obtaining blood compatible with the subject;

fractioning the blood to produce a blood component, said blood component selected from the group consisting of platelet-poor plasma, concentrated platelet-poor plasma, platelet-rich plasma, and combinations thereof;

shaping the cartilage defect to expose subchondral bone;

microfracturing the subchondral bone; and

applying the blood component to the site of the microfractured subchondral bone to substantially fill the cartilage defect with the blood component.

2 . The method of claim 1 , wherein the blood component comprises platelet-rich plasma.

3 . The method of claim 1 , further comprising resecting a portion of a surrounding cartilage at the cartilage defect.

4 . (canceled)

5 . The method of claim 1 , wherein the applying comprises delivering a sufficient amount of the blood component to provide a cartilage fill area that is substantially flush with surrounding healthy cartilage.

6 . The method of claim 1 , wherein shaping the cartilage defect to expose an underlying bone comprises removing a layer of calcified cartilage at the cartilage defect.

7 . The method of claim 2 , further comprising administering to the cartilage defect a platelet activator selected from the group consisting of thrombin, CaCl 2 , a coagulation factor, and combinations thereof.

8 . The method of claim 7 , further comprising simultaneously delivering the blood component and a platelet activator to the cartilage defect.

9 . The method of claim 8 , wherein a clot is formed in less than 30 seconds.

10 . The method of claim 2 , further comprising administering concentrated platelet-poor plasma to the cartilage defect.

Assignments (4)
RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 020362/ FRAME 0001 Recorded Nov 23, 2015
From: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
To: LVB ACQUISITION, INC.; BIOMET, INC.
Reel/Frame 037155/0133 →
CHANGE OF NAME Recorded Aug 14, 2008
From: BIOMET BIOLOGICS, INC.
To: BIOMET BIOLOGICS, LLC
Reel/Frame 021380/0803 →
SECURITY AGREEMENT Recorded Dec 10, 2007
From: LVB ACQUISITION, INC.; BIOMET, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT FOR THE SECURED PARTIES
Reel/Frame 020362/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2007
From: WOODELL-MAY, JENNIFER E.
To: BIOMET BIOLOGICS, INC.
Reel/Frame 019250/0951 →